Correspondence to editorial on "Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)".
作者信息
Liu Chuan, Yang Ling, You Hong, Teng Gao-Jun, Qi Xiaolong
机构信息
Liver Disease Center of Integrated Traditional Chinese and Western Medicine, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Nanjing, China.
Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University; State Key Laboratory of Digital Medical Engineering, Nanjing, China.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):e155-e157. doi: 10.3350/cmh.2024.0723. Epub 2024 Aug 30.
Abstract
摘要
相似文献
1
Correspondence to editorial on "Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)".致关于“卡维地洛预防经新的非侵入性模型（CHESS2306）分层的具有临床显著门静脉高压的肝硬化患者肝失代偿”的社论的信函。
Clin Mol Hepatol. 2025 Apr;31(2):e155-e157. doi: 10.3350/cmh.2024.0723. Epub 2024 Aug 30.
2
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306).卡维地洛预防肝硬化肝失代偿：基于新的非侵入性模型（CHESS2306）分层的具有临床显著门静脉高压的患者
Clin Mol Hepatol. 2025 Jan;31(1):105-118. doi: 10.3350/cmh.2024.0198. Epub 2024 Jul 11.
3
From invasive to intuitive: The emerging role of non-invasive models in hepatic decompensation: Editorial on "Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)".从侵入性到直观性：非侵入性模型在肝失代偿中的新兴作用：关于“卡维地洛预防新的非侵入性模型（CHESS2306）分层的具有临床显著门静脉高压症的肝硬化患者肝失代偿”的社论
Clin Mol Hepatol. 2025 Apr;31(2):577-580. doi: 10.3350/cmh.2024.0661. Epub 2024 Aug 19.
4
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.卡维地洛在竞争风险荟萃分析中降低了代偿性肝硬化患者失代偿和死亡的风险。
J Hepatol. 2022 Oct;77(4):1014-1025. doi: 10.1016/j.jhep.2022.05.021. Epub 2022 May 31.
5
Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China.卡维地洛预防肝硬度分层的临床显著门脉高压肝硬化失代偿的研究方案：中国一项随机、双盲、安慰剂对照、多中心试验。
BMJ Open. 2024 Jul 11;14(7):e081623. doi: 10.1136/bmjopen-2023-081623.
6
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.β 受体阻滞剂预防有临床显著门静脉高压症的肝硬化失代偿（PREDESCI）：一项随机、双盲、安慰剂对照、多中心试验。
Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22.
7
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.卡维地洛作为肝硬化和门静脉高压患者的新型非选择性β受体阻滞剂。
Liver Int. 2023 Jun;43(6):1183-1194. doi: 10.1111/liv.15559. Epub 2023 Apr 17.
8
Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis.卡维地洛与普萘洛尔预防代偿期和失代偿期肝硬化患者病情恶化及降低死亡率的比较
J Hepatol. 2024 Dec 17. doi: 10.1016/j.jhep.2024.12.017.
9
Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis.综述文章：卡维地洛和其他β受体阻滞剂在门静脉高压和肝硬化管理中应用的争议。
Aliment Pharmacol Ther. 2023 Mar;57(5):454-463. doi: 10.1111/apt.17380. Epub 2023 Jan 24.
10
Beta-blockers and cirrhosis: Striking the right balance.β受体阻滞剂与肝硬化：把握平衡。
Am J Med Sci. 2024 Apr;367(4):228-234. doi: 10.1016/j.amjms.2024.01.009. Epub 2024 Jan 21.
本文引用的文献
1
From invasive to intuitive: The emerging role of non-invasive models in hepatic decompensation: Editorial on "Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)".从侵入性到直观性：非侵入性模型在肝失代偿中的新兴作用：关于“卡维地洛预防新的非侵入性模型（CHESS2306）分层的具有临床显著门静脉高压症的肝硬化患者肝失代偿”的社论
Clin Mol Hepatol. 2025 Apr;31(2):577-580. doi: 10.3350/cmh.2024.0661. Epub 2024 Aug 19.
2
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306).卡维地洛预防肝硬化肝失代偿：基于新的非侵入性模型（CHESS2306）分层的具有临床显著门静脉高压的患者
Clin Mol Hepatol. 2025 Jan;31(1):105-118. doi: 10.3350/cmh.2024.0198. Epub 2024 Jul 11.
3
Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD.在非酒精性脂肪性肝病（NAFLD）中，肝脏硬度测量值的升高和降低与肝脏相关事件的风险独立相关。
J Hepatol. 2024 Oct;81(4):600-608. doi: 10.1016/j.jhep.2024.05.008. Epub 2024 May 16.
4
Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients.比较连续和当前的肝脏硬度测量值以预测代偿期晚期慢性肝病患者的失代偿情况。
Hepatology. 2025 Feb 1;81(2):523-531. doi: 10.1097/HEP.0000000000000891. Epub 2024 Apr 17.
5
The natural history of patients with compensated cirrhosis and elevated hepatic venous pressure gradient.代偿期肝硬化且肝静脉压力梯度升高患者的自然病史。
Portal Hypertens Cirrhosis. 2022 Sep;1(2):101-106. doi: 10.1002/poh2.27. Epub 2022 Sep 30.
6
Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis.脾脏硬度测量对代偿期晚期慢性肝病患者临床显著性门静脉高压诊断的准确性：一项系统评价和个体患者数据荟萃分析
Lancet Gastroenterol Hepatol. 2023 Sep;8(9):816-828. doi: 10.1016/S2468-1253(23)00150-4. Epub 2023 Jul 18.
7
Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease.肝硬度测量中的动力学变化可预测晚期慢性肝病的结局。
Gastroenterology. 2023 Oct;165(4):1041-1052. doi: 10.1053/j.gastro.2023.06.030. Epub 2023 Jul 11.
8
A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.一种联合 Baveno VII 和脾脏硬度算法，以改善代偿期慢性肝病患者临床显著门静脉高压的无创诊断。
Am J Gastroenterol. 2022 Nov 1;117(11):1825-1833. doi: 10.14309/ajg.0000000000001887. Epub 2022 Jul 21.
9
Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识：门静脉高压领域的新共识》
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
10
A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease.基于脾脏硬度测量和 Baveno VI 标准的联合模型排除晚期慢性肝病高危静脉曲张。
J Hepatol. 2018 Aug;69(2):308-317. doi: 10.1016/j.jhep.2018.04.023. Epub 2018 May 3.
Zotero 插件